0 code page views remaining today. Guest accounts are limited to 2 daily page views. Register free account to get more views.
Log in Register free account

Official Description

Cytomegalovirus immune globulin (CMV-IgIV), human, for intravenous use

© Copyright 2025 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 90291 refers to human cytomegalovirus immune globulin (CMV-IgIV), which is specifically formulated for intravenous use. This immunizing agent is a concentrated solution containing antibodies that provide effective, short-term passive immunity to individuals exposed to cytomegalovirus (CMV). Unlike active immunization, where the recipient's immune system is stimulated to produce its own antibodies, CMV-IgIV offers passive protection by supplying pre-formed antibodies directly into the bloodstream. These antibodies are derived from the pooled blood of multiple donors who have previously developed immunity to CMV, ensuring a robust source of protective agents. The administration of this immune globulin is crucial for individuals at high risk of CMV infection, as it helps to mitigate the potential effects of the virus without requiring the recipient's immune system to engage in antibody production. This code is specifically used to report the use of CMV-IgIV and does not encompass any additional services or procedures associated with its administration.

© Copyright 2025 Coding Ahead. All rights reserved.

1. Indications

The administration of human cytomegalovirus immune globulin (CMV-IgIV) is indicated for specific clinical scenarios where protection against cytomegalovirus is necessary. The following conditions warrant the use of this immunizing agent:

  • Prevention of CMV infection in high-risk individuals, particularly those undergoing organ transplantation or hematopoietic stem cell transplantation, where exposure to CMV can lead to severe complications.
  • Post-exposure prophylaxis for individuals who have been exposed to CMV, especially in immunocompromised patients or those with weakened immune systems.

2. Procedure

The procedure for administering human cytomegalovirus immune globulin (CMV-IgIV) involves several critical steps to ensure safety and efficacy. The following procedural steps outline the process:

  • Step 1: Patient Assessment - Prior to administration, a thorough assessment of the patient’s medical history and current health status is conducted. This includes evaluating any previous reactions to immune globulin products and determining the appropriateness of CMV-IgIV for the patient’s specific situation.
  • Step 2: Preparation of the Product - The CMV-IgIV is prepared for intravenous administration. This involves checking the product for integrity, ensuring it is within the expiration date, and following aseptic techniques to maintain sterility.
  • Step 3: Administration - The immune globulin is administered intravenously, typically through a dedicated IV line. The infusion rate is carefully monitored and adjusted based on the patient’s tolerance and any potential adverse reactions. It is essential to observe the patient closely during the infusion for any signs of allergic reactions or side effects.
  • Step 4: Post-Administration Monitoring - After the infusion, the patient is monitored for a specified period to ensure there are no immediate adverse reactions. Vital signs are checked, and the patient is observed for any signs of discomfort or complications.

3. Post-Procedure

Following the administration of CMV-IgIV, patients may require specific post-procedure care to ensure their safety and well-being. It is important to monitor the patient for any delayed reactions or side effects that may occur after the infusion. Patients should be advised to report any unusual symptoms, such as fever, rash, or difficulty breathing, to their healthcare provider. Additionally, follow-up appointments may be scheduled to assess the effectiveness of the treatment and to monitor the patient’s overall health status. Documentation of the administration, including the lot number of the immune globulin and any reactions observed, is essential for compliance and future reference.

Short Descr CMV IG IV
Medium Descr CYTOMEGALOVIRUS IMMUNE GLOBULIN HUMAN IV
Long Descr Cytomegalovirus immune globulin (CMV-IgIV), human, for intravenous use
Status Code Not Valid for Medicare Purposes
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
APC Status Indicator Non-Covered Service, not paid under OPPS
Type of Service (TOS) 1 - Medical Care
Berenson-Eggers TOS (BETOS) P6D - Minor procedures - other (non-Medicare fee schedule)
MUE 0
CCS Clinical Classification 228 - Prophylactic vaccinations and inoculations
Date
Action
Notes
2011-01-01 Changed Short description changed.
1999-01-01 Added First appearance in code book in 1999.
Code
Description
Code
Description
Code
Description